Immune system cells called regulatory T cells appear to promote cytomegalovirus (CMV) latency in the spleen of mice, but suppress it in the salivary gland. Maha Almanan of the University of Cincinnati College of Medicine, Cincinnati Children's Hospital Research Foundation, and colleagues present this surprising finding in a new study in PLOS Pathogens.
CMV infects over half of adults by the time they reach the age of 40. Usually, it causes no signs or symptoms, but it can be dangerous for people with weakened immune systems and for babies who contract it before birth. In most people, CMV settles into a latent state; its genome exists in the cells of the infected person, but it does not replicate or cause harm unless it is reactivated.
Previous work has shown that immune system cells known as regulatory T cells are associated with reactivation of CMV in immune suppressed patients. Whether or not regulatory T cells were causal in this context was unclear. In the new study, the research team investigated this role in mice by infecting them with a mouse version of CMV.
Eight months after infection, CMV had established latent infection of the spleen, salivary gland, lung, and pancreas. The mice were of a recently developed strain that allowed the researchers to then trigger a decrease in levels of regulatory T cells and examine the effects.
The results suggest that regulatory T cells can either suppress or reactivate latent CMV depending on where in the body they are acting. In the spleen, depletion of regulatory T cells reduced viral load and enhanced the functionality of immune cells whose job is to eliminate viruses. But opposite effects occurred in the salivary gland, suggesting that regulatory T cells normally prevent CMV reactivation and replication in the salivary gland.
Future work could explore whether these findings hold true in humans and why regulatory T cells have opposing effects in different mouse tissues. Better understanding of the role of regulatory T cells could aid development of treatments that manipulate their activity. Such treatments may hold particular promise for preventing CMV reactivation in patients with suppressed immune systems (eg those with HIV or organ-transplants), and are already being investigated in such patients.
In your coverage please use this URL to provide access to the freely available article in PLOS Pathogens: http://journals.
Citation: Almanan M, Raynor J, Sholl A, Wang M, Chougnet C, Cardin RD, et al. (2017) Tissue-specific control of latent CMV reactivation by regulatory T cells. PLoS Pathog 13(8): e1006507. https:/
Funding: DAH & CC received funding from the National Institute of Health grant: RO1AG033057. Funding to RDC received from National Institute of Health grant: R01 AI087683-01A1; Steinmann Family Foundation CMV Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.